Addiction - Articles - Page 6 | CARLAT PUBLISHING

EXPERT Q&A

Cannabis Use Disorder and Withdrawal

September 1, 2022

Denise Walker, PhD. Research Professor and Director of the Innovative Programs Research Group, School of Social Work, University of Washington, Seattle, WA. Co-developer of The Change Companies’ What About Marijuana Journal. Dr. Walker, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Dr. Walker reviews the clinical features of cannabis use disorder, who is most at risk, how it is similar and how it differs from other addictions, and treatment approaches. She also describes cannabis withdrawal, a syndrome that can pose a barrier to treatment, but frequently goes unrecognized.

RESEARCH UPDATE

Should Prolonged Abstinence From Alcohol Be Required Before Liver Transplant?

July 1, 2022

Deepti Anbarasan, MD. and Sonya Bakshi, MD

Sonya Bakshi, MD, and Deepti Anbarasan, MD.

Dr. Bakshi and Dr. Anbarasan, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Patients with alcohol-associated liver disease have traditionally needed to demonstrate an ability to refrain from drinking for 6 months before being deemed eligible for a liver transplant, despite the absence of research findings to support this requirement. Findings from this retrospective study show that a waiting period is not associated with improved outcomes.

What You Need to Know About Vaping

June 13, 2022

Noah Capurso, MD, MHS and Sivabalaji Kaliamurthy, MD

Why is it important for providers to understand how vaping devices work and what type of information should we be providing our patients with?

Suicide Safety Planning for the Patient with Addiction

November 5, 2021

Jessica Casella, LCSW

Jessica Casella, LCSW Private practice social worker, Branford, CT. Adjunct faculty member at Sacred Heart University School of Social Work. Active member of the state of Connecticut’s Suicide Advisory Board. Ms. Casella has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Addiction is a major risk factor for suicide. Here, we provide a practical guide to Safety Planning, an evidenced based approach for reducing suicide risk that can be implemented in a variety of clinical settings.

The Continuing Challenge of Designer Drugs

September 10, 2021

Marilyn A. Huestis, PhD

Marilyn A. Huestis, PhD

Senior fellow at the Institute on Emerging Health Professions, Thomas Jefferson University. Former Chief of the Chemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse (NIA). Dr. Huestis has disclosed that she has received payment as a consultant for Dynacare Laboratories, which provides lab testing.

Dr. Capurso has reviewed this article and found no evidence of bias in this educational activity.

Designer drugs is a catchall term for a large group of illicit substances that can have disparate effects. Dr. Huestis provides an in depth look at the current state of designer drugs, what clinicians should be wary of, and treatment options.

Disulfiram: An Underused Strategy for Alcohol Use Disorders

June 29, 2021

Stephen Wyatt, DO.

Stephen Wyatt, DO. Private practice psychiatrist with certification in addiction psychiatry, Charlotte, NC. Dr. Wyatt has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We unravel the myths that keep psychiatrists from using disulfiram (Antabuse) in alcohol use disorders. In the right patient, this medication is very effective and far less dangerous than the alternative: continued drinking.

EXPERT Q&A

Opioid Use Disorders and Serious Mental Illness

December 10, 2020

Sandra Gomez-Luna, MD

Sandra Gomez-Luna, MD
Clinical Assistant Professor at Yale University. Adult, adolescent, and child psychiatrist in Darien, CT. Dr. Gomez-Luna has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Those with serious mental illness and unhealthy opioid use have special treatment considerations due to polypharmacy and overlapping stigma. Dr. Gomez-Luna walks us through these nuances and explains microdosing of buprenorphine—a helpful technique for starting treatment in patients who may have other opioids on board.

CLINICAL UPDATE

Despair, Loneliness, and Substance Use Disorders

October 21, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Loneliness is a readily measurable phenomenon and it predicts worse outcomes in addiction treatment on the individual and population levels. What can we do in the clinic to combat loneliness and promote social cohesion?

EXPERT Q&A

Telemedicine for Addiction Treatment: Evidence and Implementation Strategies

August 6, 2020

Dallas Swendeman, PhD, MPH

Dallas Swendeman, PhD, MPH
Associate Professor, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA Dr. Swendeman has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

As many clinicians embark on new telemedicine efforts, we review the body of literature around virtual approaches to the care of patients with addiction. Dr. Swendeman reviews the evidence of efficacy for electronic self-monitoring, text-messaging, and other strategies may support your practice, and how to implement them.

EXPERT Q&A

Personal Privacy Versus Public Safety: Addiction Among Health Professionals

March 30, 2020

Paul H. Earley, MD, DFASAM

Paul H. Earley, MD, DFASAM
Medical director of the Georgia Professionals Health Program, Inc. Distinguished Fellow of ASAM. President of the Federation of State Physician Health Programs. Dr. Earley has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Paul Earley, president-elect of the Federation of Physician Health Programs, outlines the offerings of physician health programs, how to engage yourself or colleagues in treatment, and how treatment may interface with medical boards.